US 6780413
Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
expired A61KA61K2039/505A61K47/6819
Quick answer
US patent 6780413 (Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Aug 24 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K47/6819, A61K47/6821, A61K47/6827